Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer

NCT00102219 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00102219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2004
Completion date
October 31, 2007
Enrollment
77 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer